TRAIL and apoptosis induction by TNF-family death receptors

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Oncogene

• Publication date

  2003-11-24

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/sj.onc.1207232PMID 14634624
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Death receptors and melanoma resistance to apoptosis

  2003cited by this paper
• Adenoviral gene transfer of tumor necrosis factor-related apoptosis-inducing ligand overcomes an impaired response of hepatoma cells but causes severe apoptosis in primary human hepatocytes.

  2003cited by this paper
• The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells

  2003cited by this paper
• Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis is an important endogenous mechanism for resistance to liver metastases in murine renal cancer.

  2003cited by this paper
• Stabilization of p53 by CP-31398 Inhibits Ubiquitination without Altering Phosphorylation at Serine 15 or 20 or MDM2 Binding

  2003cited by this paper
• PG490-mediated sensitization of lung cancer cells to Apo2L/TRAIL-induced apoptosis requires activation of ERK2

  2003cited by this paper
• Cell surface Death Receptor signaling in normal and cancer cells.

  2003cited by this paper
• Defective thymocyte apoptosis and accelerated autoimmune diseases in TRAIL−/− mice

  2003cited by this paper
• Nature's TRAIL--on a path to cancer immunotherapy.

  2003cited by this paper
• Apo2L/TRAIL and its death and decoy receptors

  2003cited by this paper
• Targeting death and decoy receptors of the tumour-necrosis factor superfamily

  2002cited by this paper
• Tumor-cell resistance to death receptor–induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax

  2002cited by this paper
• Defining characteristics of Types I and II apoptotic cells in response to TRAIL.

  2002cited by this paper
• Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells.

  2002cited by this paper
• Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: a statistical analysis of information in the National Cancer Institute database.

  2002cited by this paper
• Requirement of BAX for TRAIL/Apo2L-induced apoptosis of colorectal cancers: synergism with sulindac-mediated inhibition of Bcl-x(L).

  2002cited by this paper
• TRAIL-induced apoptosis requires Bax-dependent mitochondrial release of Smac/DIABLO.

  2002cited by this paper
• Increased Susceptibility to Tumor Initiation and Metastasis in TNF-Related Apoptosis-Inducing Ligand-Deficient Mice1

  2002cited by this paper
• Long-term tumor-free survival from treatment with the GFP–TRAIL fusion gene expressed from the hTERT promoter in breast cancer cells

  2002cited by this paper
• Antitumor activity and prolonged expression from a TRAIL-expressing adenoviral vector.

  2002cited by this paper
• T cells require TRAIL for optimal graft-versus-tumor activity

  2002cited by this paper
• An Inducible Pathway for Degradation of FLIP Protein Sensitizes Tumor Cells to TRAIL-induced Apoptosis*

  2002cited by this paper
• c‐FLIPL is a dual function regulator for caspase‐8 activation and CD95‐mediated apoptosis

  2002cited by this paper
• Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo

  2002cited by this paper
• The Mutant p53-Conformation Modifying Drug, CP-31398, Can Induce Apoptosis

  2002cited by this paper
• Insights into cancer therapeutic design based on p53 and TRAIL receptor signaling

  2001cited by this paper
• Cancer gene therapy: fringe or cutting edge?

  2001cited by this paper
• Inactivation of the apoptosis effector Apaf-1 in malignant melanoma

  2001cited by this paper
• Cell type specific involvement of death receptor and mitochondrial pathways in drug-induced apoptosis

  2001cited by this paper
• Genasense (Genta Inc).

  2001cited by this paper
• Differential Secretion of Fas Ligand- or APO2 Ligand/TNF-Related Apoptosis-Inducing Ligand-Carrying Microvesicles During Activation-Induced Death of Human T Cells1

  2001cited by this paper
• Resistance to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in neuroblastoma cells correlates with a loss of caspase-8 expression.

  2001cited by this paper
• Pro-survival Function of Akt/Protein Kinase B in Prostate Cancer Cells

  2001cited by this paper
• How melanoma cells evade trail-induced apoptosis

  2001cited by this paper
• A Molecular Whodunit

  2001cited by this paper
• Apoptosis. Till death us do part.

  2001cited by this paper
• Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of human melanoma is regulated by smac/DIABLO release from mitochondria.

  2001cited by this paper
• The potential of TRAIL for cancer chemotherapy

  2001cited by this paper
• Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells

  2001cited by this paper
• Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand

  2000cited by this paper
• Temperature-sensitive Differential Affinity of TRAIL for Its Receptors

  2000cited by this paper
• Molecular determinants of response to TRAIL in killing of normal and cancer cells.

  2000cited by this paper
• Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition.

  2000cited by this paper
• Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins.

  2000cited by this paper
• Cysteine 230 Is Essential for the Structure and Activity of the Cytotoxic Ligand TRAIL*

  2000cited by this paper
• Apoptotic pathways: paper wraps stone blunts scissors.

  2000cited by this paper
• The caspase 9 inhibitor Z-LEHD-FMK protects human liver cells while permitting death of cancer cells exposed to tumor necrosis factor-related apoptosis-inducing ligand.

  2000cited by this paper
• Tumoricidal activity of tumor necrosis factor–related apoptosis–inducing ligand in vivo

  1999cited by this paper
• Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma.

  1999cited by this paper
• Pharmacological rescue of mutant p53 conformation and function.

  1999cited by this paper
• Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5.

  1999cited by this paper
• Structure of the TRAIL–DR5 complex reveals mechanisms conferring specificity in apoptotic initiation

  1999cited by this paper
• The proteasome inhibitor PS-341 in cancer therapy.

  1999cited by this paper
• Safety and antitumor activity of recombinant soluble Apo2 ligand.

  1999cited by this paper
• The Bcl-2 protein family: arbiters of cell survival.

  1998cited by this paper
• Inhibition of fas death signals by FLIPs.

  1998cited by this paper
• Death receptors: signaling and modulation.

  1998cited by this paper
• Two CD95 (APO‐1/Fas) signaling pathways

  1998cited by this paper
• Surface expression of TRAIL/Apo‐2 ligand in activated mouse T and B cells

  1998cited by this paper
• bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice

  1998cited by this paper
• Osteoprotegerin Is a Receptor for the Cytotoxic Ligand TRAIL*

  1998cited by this paper
• An antagonist decoy receptor and a death domain-containing receptor for TRAIL.

  1997influential reference
• How TRAIL Kills Cancer Cells, But Not Normal Cells

  1997cited by this paper
• A novel receptor for Apo2L/TRAIL contains a truncated death domain.

  1997cited by this paper
• Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors.

  1997cited by this paper
• Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappaB pathway.

  1997cited by this paper
• The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain.

  1997cited by this paper
• KILLER/DR5 is a DNA damage–inducible p53–regulated death receptor gene

  1997cited by this paper
• The Receptor for the Cytotoxic Ligand TRAIL

  1997influential reference
• TRAIL‐R2: a novel apoptosis‐mediating receptor for TRAIL

  1997cited by this paper
• Identification and characterization of a new member of the TNF family that induces apoptosis.

  1995cited by this paper

• Decoy Receptors in Autoimmunity: Molecular Guardians and Pathogenic Players in Immune Dysregulation

  2026cites this paper
• Targeted Therapy for CD13‐Overexpressing Triple‐Negative Breast Cancers Using Apoptosis‐Inducing Protein Cage Nanoparticles

  2026cites this paper
• Zerumbone enhances TRAIL-induced apoptosis via USP9x-mediated downregulation of Mcl-1.

  2025cites this paper
• Recent Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Engineering Strategies for Precise Strike Therapy against Tumor

  2025cites this paper
• Clinical Applications of HDAC Inhibitors as Anticancer Agents in Prostate, Breast, Ovarian, and Cervical Cancers

  2025cites this paper
• The Combination of PF-543 and TRAIL Effectively Induces Apoptotic Cell Death and Inhibits Stem Cell-Like Properties Through the SPHK1/S1PR1/STAT3 Pathway in TRAIL-Resistant Colorectal Cancer Cells

  2025cites this paper
• Identification of Potential Molecular Targets of Doxorubicin for Application in Skin Cancer: A Network Pharmacology and Molecular Docking Perspective.

  2025cites this paper
• Thioester platform to develop potential nanomedicines for breast cancer therapy

  2025cites this paper
• Co-delivery of TRAIL DNA and salinomycin for cancer therapy via enhanced apoptosis and cancer stemness inhibition.

  2025cites this paper
• Chaetocin enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis by enhancing DR5 stabilization and reactive oxygen species generation in human glioblastoma cells

  2025cites this paper
• Changes of nanoviscosity during TRAIL-induced apoptosis of HeLa cells

  2025cites this paper
• Current approaches overcome the limit of TRAIL-based treatment in colorectal cancer: From fusion protein to nano-delivery platform.

  2025cites this paper
• Compact clustering of highly oligomerized anti-DR5 nanobodies effectively drives apoptotic cancer cell death, significantly suppressing tumor growth

  2025cites this paper
• DR5 is a restriction factor for human herpesviruses

  2025cites this paper
• ANXA2 in cancer: aberrant regulation of tumour cell apoptosis and its immune interactions

  2025cites this paper
• TRAIL-resistant glioma cells resist Withania somnifera mediated apoptosis via USP5 upregulation

  2025cites this paper
• Artificial intelligence analysis applied to the treatment of granulosa cell tumors of the ovary

  2025cites this paper
• Review of BCG immunotherapy for bladder cancer

  2025cites this paper
• Integrating AI/ML and multi-omics approaches to investigate the role of TNFRSF10A/TRAILR1 and its potential targets in pancreatic cancer

  2025cites this paper
• Comparative Assessment of Various Formats of TRAIL in Three-Dimensional Cell Culture and Patient-Derived Tumoroids of Colorectal Cancer.

  2025cites this paper
• The potential role of hydrogen sulfide in cancer cell apoptosis

  2024cites this paper
• Myeloid-T cell interplay and cell state transitions associated with checkpoint inhibitor response in melanoma.

  2024cites this paper
• Mechanisms and therapeutic prospect of the JAK-STAT signaling pathway in liver cancer

  2024cites this paper
• Combining the constitutive TRAIL-secreting induced neural stem cell therapy with the novel anti-cancer drug TR-107 in glioblastoma

  2024cites this paper
• Liposomes and Their Therapeutic Applications in Enhancing Psoriasis and Breast Cancer Treatments

  2024cites this paper
• The Association of Death Receptors and TGF-β1 Expression in Urothelial Bladder Cancer and Their Prognostic Significance

  2024cites this paper
• Development of a biocompatible 3D hydrogel scaffold using continuous liquid interface production for the delivery of cell therapies to treat recurrent glioblastoma

  2024cites this paper
• Targeted treatment of chondrosarcoma with a bacteriophage-based particle delivering a secreted tumor necrosis factor-related apoptosis-inducing ligand

  2024cites this paper
• Enhanced anticancer efficacy of TRAIL-conjugated and odanacatib-loaded PLGA nanoparticles in TRAIL resistant cancer.

  2024cites this paper
• Spatial distribution of tumor-associated macrophages in an orthotopic prostate cancer mouse model.

  2024cites this paper
• Exploring candidate biomarkers for rheumatoid arthritis through cardiovascular and cardiometabolic serum proteome profiling

  2024cites this paper
• Caloric restriction leads to druggable LSD1-dependent cancer stem cells expansion

  2024cites this paper
• Canonical and Noncanonical Functions of the BH3 Domain Protein Bid in Apoptosis, Oncogenesis, Cancer Therapeutics, and Aging

  2024cites this paper
• A comprehensive bioinformatics analysis to identify potential prognostic biomarkers among TNFSF superfamily in breast cancer

  2024cites this paper
• In situ vaccination caused by diverse irradiation-driven cell death programs

  2024cites this paper
• Isolation of bioactive phytochemicals from Crinum asiaticum L. along with their cytotoxic and TRAIL-resistance abrogating prospect assessment

  2024cites this paper
• Revealing the key role of cuproptosis in osteoporosis via the bioinformatic analysis and experimental validation of cuproptosis-related genes

  2024cites this paper
• A Network Map of Intracellular Alpha‐Fetoprotein Signalling in Hepatocellular Carcinoma

  2024cites this paper
• TRAIL receptors as prognostic markers and survival predictors in ovarian cancer: A systematic review of clinical studies and meta-analysis

  2024cites this paper
• Current study of pathogenetic mechanisms and therapeutics of chronic atrophic gastritis: a comprehensive review

  2024cites this paper
• Microorganism‐Derived Bisindole Alkaloids With Anticancer Potential and Their Mechanisms: A Comprehensive Review

  2024cites this paper
• Cell death in glioblastoma and the central nervous system

  2024cites this paper
• Uncovering immune cell-associated genes in breast cancer: based on summary data-based Mendelian randomized analysis and colocalization study

  2024cites this paper
• Rhein: An Updated Review Concerning Its Biological Activity, Pharmacokinetics, Structure Optimization, and Future Pharmaceutical Applications

  2024cites this paper
• Cell death in cancer chemotherapy using taxanes

  2024cites this paper
• Comprehensive study of molecular mechanism in Cervical Cancer cell death in vitro and in vivo induced by Phytochemicals

  2024cites this paper
• Antitumor activity of genetically engineered NK-cells in non-hematological solid tumor: a comprehensive review

  2024cites this paper
• Immunotherapy Using Activated Natural Killer Cells Improves Postoperative Neutrophil-to-Lymphocyte Ratio and Long-Term Prognosis of Living Donor Liver Transplant Recipients With Hepatocellular Carcinoma.

  2024cites this paper
• Effect of Abdominal Aortic Calcification on Recurrence Following Initial Hepatectomy for Colorectal Liver Metastases

  2024cites this paper
• Genistein Enhances TRAIL-Mediated Apoptosis Through the Inhibition of XIAP and DcR1 in Colon Carcinoma Cells Treated with 5-Fluorouracil

  2023cites this paper
• Therapeutic Potential of Luteolin on Cancer

  2023cites this paper
• Nano-TRAIL: a promising path to cancer therapy

  2023cites this paper
• Broadening horizons in mechanisms, management, and treatment of diabetic kidney disease.

  2023cites this paper
• Nimesulide, a COX-2 inhibitor, sensitizes pancreatic cancer cells to TRAIL-induced apoptosis by promoting DR5 clustering †

  2023cites this paper
• Docetaxel Enhances Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Mediated Apoptosis in Prostate Cancer Cells via Epigenetic Gene Regulation by Enhancer of Zeste Homolog 2

  2023cites this paper
• Therapeutic targeting of TRAIL death receptors

  2023cites this paper
• Single-cell RNA-sequencing of PBMCs from SAVI patients reveals disease-associated monocytes with elevated integrated stress response

  2023cites this paper
• Exosome-Transmitted tRF-16-K8J7K1B Promotes Tamoxifen Resistance by Reducing Drug-Induced Cell Apoptosis in Breast Cancer

  2023cites this paper
• Neuraminidase 4 (NEU4): new biological and physiological player.

  2023cites this paper
• Multi-CpG linear regression models to accurately predict paclitaxel and docetaxel activity in cancer cell lines.

  2023cites this paper
• Mesenchymal Stem Cell Microvesicles from Adipose Tissue: Unraveling Their Impact on Primary Ovarian Cancer Cells and Their Therapeutic Opportunities

  2023cites this paper
• Natural products and the balancing act of autophagy-dependent/independent ferroptosis in cancer therapy

  2023cites this paper
• Interferon signaling drives epithelial metabolic reprogramming to promote secondary bacterial infection

  2023cites this paper
• An Antidepressant Drug Increased TRAIL Receptor-2 Expression and Sensitized Lung Cancer Cells to TRAIL-induced Apoptosis

  2023cites this paper
• The role of the immune response and inflammatory pathways in TNF-related apoptosis-inducing ligand (TRAIL) resistance in triple-negative breast cancer cells.

  2023cites this paper
• Panoramic Dental X-ray Exposure Leads to Oxidative stress, Inflammation and Apoptosis-mediated Developmental Defects in Zebrafish Embryos.

  2023cites this paper
• p53 stabilisation potentiates [177Lu]Lu-DOTATATE treatment in neuroblastoma xenografts

  2023cites this paper
• Effector and cytolytic function of natural killer cells in anti-cancer immunity.

  2023cites this paper
• IL-1β stimulated human umbilical cord mesenchymal stem cells ameliorate rheumatoid arthritis via inducing apoptosis of fibroblast-like synoviocytes

  2023cites this paper
• Chaetocin-mediated SUV39H1 inhibition targets stemness and oncogenic networks of diffuse midline gliomas and synergizes with ONC201.

  2023cites this paper
• Apoptosis and Phagocytosis as Antiviral Mechanisms.

  2023cites this paper
• TSC2 regulates tumor susceptibility to TRAIL‐mediated T‐cell killing by orchestrating mTOR signaling

  2023cites this paper
• TRAIL promotes the polarization of human macrophages toward a proinflammatory M1 phenotype and is associated with increased survival in cancer patients with high tumor macrophage content

  2023cites this paper
• Antibody-dependent cellular cytotoxicity-inducing antibodies enhance the natural killer cell anti-cancer response against patient-derived pancreatic cancer organoids

  2023cites this paper
• Palmitoylation in apoptosis

  2023cites this paper
• Dihydroaustrasulfone alcohol induces apoptosis in nasopharyngeal cancer cells by inducing reactive oxygen species-dependent inactivation of the PI3K/AKT pathway

  2023cites this paper
• Blocking TRAIL-DR5 signaling pathway with soluble death receptor 5 fusion protein mitigates radiation-induced injury

  2023cites this paper
• Molecular mechanisms underlying the clinical efficacy of panobinostat involve Stochasticity of epigenetic signaling, sensitization to anticancer drugs, and induction of cellular cell death related to cellular stresses.

  2023cites this paper
• The effects of IL-1β stimulated human umbilical cord mesenchymal stem cells on polarization and apoptosis of macrophages in rheumatoid arthritis

  2023cites this paper
• Arteriosclerosis Decreases Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Expression on Liver Natural Killer Cells in Living Donor Liver Transplantation.

  2023cites this paper
• Endometrial apoptotic markers NF-kB, BCL2 and Caspase-8 expression in patients with external genital endometriosis and chronic endometritis

  2023cites this paper
• Single-cell RNA-sequencing of PBMCs from SAVI patients reveals disease-associated monocytes with elevated integrated stress response

  2023cites this paper
• Ceramide Analog 5cc Overcomes TRAIL Resistance by Enhancing JNK Activation and Repressing XIAP Expression in Metastatic Colon Cancer Cells

  2023cites this paper
• The Role of TRAIL in Apoptosis and Immunosurveillance in Cancer

  2023cites this paper
• Cell competition for cancer treatment with Urine Progenitor Cells

  2023cites this paper
• Carboxypeptidase A4 negatively regulates HGS-ETR1/2-induced pyroptosis by forming a positive feedback loop with the AKT signalling pathway

  2023cites this paper
• Trans-differentiation of trophoblast stem cells: implications in placental biology

  2022influential citation
• Overview of Cancer Metabolism and Signaling Transduction

  2022cites this paper
• TRAIL inhibition by soluble death receptor 5 protects against acute myocardial infarction in rats

  2022cites this paper
• Exosomal delivery of TRAIL and miR-335 for the treatment of hepatocellular carcinoma (Review)

  2022cites this paper
• Combining of Oncolytic Virotherapy and Other Immunotherapeutic Approaches in Cancer: A Powerful Functionalization Tactic

  2022cites this paper
• Probiotics as multifaceted oral vaccines against colon cancer: A review

  2022cites this paper
• Anticancer peptides mechanisms, simple and complex.

  2022cites this paper
• Neutrophils as immune effector cells in antibody therapy in cancer

  2022cites this paper
• Escaping cell death via TRAIL decoy receptors: a systematic review of their roles and expressions in colorectal cancer

  2022cites this paper
• Radiation-induced Cell Death and Its Mechanisms

  2022cites this paper
• Development of synthetic lipoxin-A4 mimetics (sLXms): New avenues in the treatment of cardio-metabolic diseases.

  2022cites this paper
• TSC2 regulates tumor susceptibility to TRAIL-mediated T cell killing by orchestrating mTOR signaling

  2022cites this paper
• Serum MicroRNAs Predict Isolated Rapid Eye Movement Sleep Behavior Disorder and Lewy Body Diseases

  2022cites this paper
• Osteomimicry

  2022cites this paper